Table 3

OR and 95% CI for breast cancer in tertiles of enterolactone/creatinin and genistein/creatinin according to follow-up period

CasesControlsORa (95% CI)Test for trendb
1–3 yr before diagnosis
 Enterolactone/creatininec
  7.16–379.0 (235.6)9321P = 0.15
  379.1–655.9 (501.3)7310.80 (0.26–2.42)
  656.0–2334.9 (969.9)12221.94 (0.70–5.38)
 Genistein/creatininc
  10.2–67.1 (48.4)12241P = 0.20
  67.2–112.2 (87.8)9340.53 (0.19–1.45)
  112.3–523.8 (196.6)7270.52 (0.18–1.53)
4–5 yr before diagnosis
 Enterolactone/creatininc
  7.16–379.0 (235.6)7311P = 0.35
  379.1–655.9 (501.3)10192.33 (0.76–7.12)
  656.0–2334.9 (969.9)9281.42 (0.47–4.33)
 Genistein/creatininc
  10.2–67.1 (48.4)8221P = 0.75
  67.2–112.2 (87.8)9250.99 (0.33–3.01)
  112.3–523.8 (196.6)10310.89 (0.30–2.61)
6+ yr before diagnosis
 Enterolactone/creatininc
  7.16–379.0 (235.6)10281P = 0.50
  379.1–655.9 (501.3)10440.64 (0.24–1.72)
  656.0–2334.9 (969.9)13331.10 (0.42–2.90)
 Genistein/creatininc
  10.2–67.1 (48.4)11401P = 0.87
  67.2–112.2 (87.8)12331.32 (0.52–3.38)
  112.3–523.8 (196.6)10321.14 (0.43–3.01)
  • a Crude OR.

  • b For multivariate analyses, based on the median values of the tertiles.

  • c Range, μmol/mol; numbers in parentheses, mean.